Targets › P4HTM
1 program from 1 company in 5 trials: 2 Phase 3, 2 Phase 1, 1 Phase 4; Genitourinary, Hematology, Psychiatry; next expected readout Oct 2027.
Catalyzes the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates HIF1A at 'Pro-402' and 'Pro-564'. May function as a cellular oxygen sensor and, under normoxic conditions, may target HIF through the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. (UniProt, Q9NXG6)
Open in Phaseline: the race on P4HTM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Astellas | Roxadustat Hypoxia-inducible factor prolyl hydroxylase inhibitor | EGLN2, P4HTM, EGLN1, EGLN3 | Phase 3 | Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic … | Oct 2027 |
Chronic Kidney Disease (1) Dialysis; Complications (1) Perioperative Anemia (1) Kidney Failure, Chronic (1) Kidney Failure,Chronic (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.